InvestorWire NewsRoom


Brain Scientific Inc. (BRSF) Tech to be Used in a Ketamine Clinical Study for Mental Health Care
June 15, 2021

Brain Scientific Inc. (BRSF) Tech to be Used in a Ketamine Clinical Study for Mental Health Care

  • Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
  • BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more. 
  • The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to

Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat brain disorders or diseases. By partnering with BRSF, they will leverage both data and AI to correlate biomarkers to identify chronic pain, depression, PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia. 

The trial will begin the second half of 2021 and will need to enroll 35 patients. Ehave will be studying the effect of ketamine as a treatment for major depression while assessing the candidate therapy’s safety and tolerability.

Mental health disorders, in the wake of Covid-19, are on the rise. Depression alone affects over 264 million worldwide, and drug overdoses have risen 42% since the pandemic began. 

“Ehave’s goal,” stated Alfred Farrington II, CIO of Ehave, “is to help practitioners make more informed decisions about mental health care. We believe the data from this clinical trial will provide longitudinal insights that can link brain analysis and psychedelics.” 

Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the brain areas impacted by the treatment. This study has the potential to create new forms of treatment for chronic mental health disorders.

BRSF’s neurological devices, NeuroCap(TM) and NeuroEEG(TM) are portable, clinical-grade, cost-efficient, easy-to-use, and allow for long-term monitoring. In addition to these benefits, BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected.  

Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market. 

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).